Literature DB >> 22692561

The role of targeted therapy and biomarkers in breast cancer treatment.

Alison T Stopeck1, Ursa Brown-Glaberman, Hong Yuen Wong, Ben Ho Park, Sara E Barnato, William J Gradishar, Clifford A Hudis, Hope S Rugo.   

Abstract

Breast cancer is the most prevalent life-threatening cancer in women and the second leading cause of cancer associated deaths. Consequently, optimizing breast cancer therapy to increase cure rates in early stage disease and improve life expectancy and palliation for patients with metastasis is a critical need and major area of research in medical oncology. This article focuses on the development of personalized therapy in breast cancer though the use of targeted therapies and their associated biomarkers. Topics reviewed include the historic advances in targeting the HER2 receptor and the current avenues being studied to circumvent resistance; new developments in the management of triple negative and metastatic breast cancer; and the challenges and pitfalls associated with targeting angiogenesis. Using these as examples, many of the innovations and challenges in the treatment of women with breast cancer are explored.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22692561     DOI: 10.1007/s10585-012-9496-y

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  77 in total

1.  Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Authors:  Anand G Patel; Silvana B De Lorenzo; Karen S Flatten; Guy G Poirier; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-01-30       Impact factor: 12.531

Review 2.  Antiangiogenic strategies in breast cancer management.

Authors:  Monica Giovannini; Daniela Aldrighetti; Patrizia Zucchinelli; Carmen Belli; Eugenio Villa
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-11       Impact factor: 6.312

Review 3.  Circulating endothelial cells as biomarkers in clinical oncology.

Authors:  Patrizia Mancuso; Francesco Bertolini
Journal:  Microvasc Res       Date:  2010-02-20       Impact factor: 3.514

4.  Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.

Authors:  Angelica Calleri; Anna Bono; Vincenzo Bagnardi; Jessica Quarna; Patrizia Mancuso; Cristina Rabascio; Silvia Dellapasqua; Elisabetta Campagnoli; Yuval Shaked; Aron Goldhirsch; Marco Colleoni; Francesco Bertolini
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

5.  Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Authors:  Harold J Burstein; Yan Sun; Luc Y Dirix; Zefei Jiang; Robert Paridaens; Antoinette R Tan; Ahmad Awada; Anantbhushan Ranade; Shunchang Jiao; Gary Schwartz; Richat Abbas; Christine Powell; Kathleen Turnbull; Jennifer Vermette; Charles Zacharchuk; Rajendra Badwe
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

Review 6.  Dissecting the heterogeneity of triple-negative breast cancer.

Authors:  Otto Metzger-Filho; Andrew Tutt; Evandro de Azambuja; Kamal S Saini; Giuseppe Viale; Sherene Loi; Ian Bradbury; Judith M Bliss; Hatem A Azim; Paul Ellis; Angelo Di Leo; José Baselga; Christos Sotiriou; Martine Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

7.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

8.  Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.

Authors:  Patrizia Mancuso; Marco Colleoni; Angelica Calleri; Laura Orlando; Patrick Maisonneuve; Giancarlo Pruneri; Alice Agliano; Aron Goldhirsch; Yuval Shaked; Robert S Kerbel; Francesco Bertolini
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

9.  Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.

Authors:  Giuseppe Viale; Nicole Rotmensz; Patrick Maisonneuve; Luca Bottiglieri; Emilia Montagna; Alberto Luini; Paolo Veronesi; Mattia Intra; Rosalba Torrisi; Anna Cardillo; Elisabetta Campagnoli; Aron Goldhirsch; Marco Colleoni
Journal:  Breast Cancer Res Treat       Date:  2008-10-07       Impact factor: 4.872

10.  Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

Authors:  B K Linderholm; H Hellborg; U Johansson; G Elmberger; L Skoog; J Lehtiö; R Lewensohn
Journal:  Ann Oncol       Date:  2009-06-23       Impact factor: 32.976

View more
  18 in total

1.  PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer.

Authors:  R-K Li; J- Gao; L-H Guo; G-Q Huang; W-H Luo
Journal:  Cancer Gene Ther       Date:  2017-07-21       Impact factor: 5.987

2.  LETM1 overexpression is correlated with the clinical features and survival outcome of breast cancer.

Authors:  Nan Li; Yahui Zheng; Chouhui Xuan; Zhenhua Lin; Longzhen Piao; Shuangping Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Biocompatible nanopolymers: the next generation of breast cancer treatment?

Authors:  Julia Y Ljubimova; Eggehard Holler
Journal:  Nanomedicine (Lond)       Date:  2012-10       Impact factor: 5.307

4.  Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer.

Authors:  Clodoaldo Zago Campos; Roberta Losi Guembarovski; Carlos Eduardo Coral de Oliveira; Bruna Karina Banin Hirata; Glauco Akelinghton Freire Vitiello; Flávia Luísa Dias; Carlos Hiroji Hiroki; Maria Angelica Ehara Watanabe; Tânia Longo Mazzuco
Journal:  Clin Exp Med       Date:  2017-04-28       Impact factor: 3.984

5.  Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.

Authors:  Juan Garona; Marina Pifano; Maria B Pastrian; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Clin Exp Metastasis       Date:  2016-05-05       Impact factor: 5.150

6.  Huaier Extract Induces Autophagic Cell Death by Inhibiting the mTOR/S6K Pathway in Breast Cancer Cells.

Authors:  Xiaolong Wang; Wenwen Qi; Yaming Li; Ning Zhang; Lun Dong; Mingjuan Sun; Jinjing Cun; Yan Zhang; Shangge Lv; Qifeng Yang
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

7.  USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α.

Authors:  Jiawei Cao; Du Wu; Guang Wu; Yaqi Wang; Tianhao Ren; Yang Wang; Yingshuai Lv; Wei Sun; Jieyi Wang; Changrui Qian; Licai He; Kaiyan Yang; Hongzhi Li; Haihua Gu
Journal:  Cell Death Dis       Date:  2021-06-15       Impact factor: 8.469

8.  Survival prediction score: a simple but age-dependent method predicting prognosis in patients undergoing palliative radiotherapy.

Authors:  Kent Angelo; Astrid Dalhaug; Adam Pawinski; Ellinor Haukland; Carsten Nieder
Journal:  ISRN Oncol       Date:  2014-03-19

9.  The expression and clinical significance of HERC4 in breast cancer.

Authors:  Hui Zhou; Rong Shi; Min Wei; Wen-Ling Zheng; Jue-Yu Zhou; Wen-Li Ma
Journal:  Cancer Cell Int       Date:  2013-11-14       Impact factor: 5.722

10.  Clinical implications of high NQO1 expression in breast cancers.

Authors:  Yang Yang; Yan Zhang; Qunying Wu; Xuelian Cui; Zhenhua Lin; Shuangping Liu; Liyan Chen
Journal:  J Exp Clin Cancer Res       Date:  2014-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.